Paschalis Evangelidis: A New Way to Treat iTTP by Targeting the Autoimmune Process
Paschalis Evangelidis, Former Teaching Assistant at Aristotle University of Thessaloniki (AUTH) shared a post on LinkedIn about a recent article he and Eleni Gavriilaki co-authored, adding:
”Excited to share our insightful commentary on immune-mediated thrombotic thrombocytopenic purpura (iTTP):
This piece highlights a promising shift in how we think about iTTP – not just managing acute episodes, but targeting the underlying autoimmune process.
A novel approach using red blood cells to deliver ADAMTS13 antigens in an ‘immune-silent’ way could help induce immune tolerance and reduce relapses.
While still early, this strategy opens the door to more precise, long-term solutions beyond conventional immunosuppression.
A small but meaningful step toward solving another piece of the TTP puzzle.”
Title: Solving another piece of the thrombotic thrombocytopenic purpura puzzle?
Authors: Paschalis Evangelidis, Eleni Gavriilaki
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 4, 2026, 16:17Nada Fahd: Immune Thrombocytopenia (ITP) – Outpatient vs Inpatient Management
-
Jun 4, 2026, 16:16Saoud Hassan: Hemostasis and Blood Coagulation Pathway – Simplified
-
Jun 4, 2026, 16:15Farooq Khan: Vacuuming Blood Clots in Seconds
-
Jun 4, 2026, 16:14Kayla Garrett: Confirming Or Excluding APS Relies On Accurate Lupus Anticoagulant Testing
-
Jun 4, 2026, 16:14Scott Colton: Exploring the Key Differences Between Anticoagulant and Antiplatelet Medications
-
Jun 4, 2026, 16:13Wolfgang Miesbach: Is Bone Health a Silent Comorbidity In Haemophilia and VWD?
-
Jun 4, 2026, 15:35Carolina La Mura: Insights from the LATAM Hemophilia Forum 2026
-
Jun 4, 2026, 15:25Heba Youssef: Anticoagulation Bridging – A Clinical Summary Every Practitioner Should Know
-
Jun 4, 2026, 15:10Dipanjana Datta: Genetic Spectrum of Hemophilia and Carrier Screening in Families of Persons with Hemophilia